Drugs / Gamunex
Gamunex
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06305793 | Mar 2024 → Mar 2026 overdue | long COVID-19 | Kanecia Obie Zimmerman | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gamunex | “IVIG (Gamunex); 2g /kg monthly for 9 months (36 weeks)” NCT06305793 ↗ |
| Known as | intravenous immunoglobulin | “pharmacotherapy with intravenous immunoglobulin (IVIG)” PMID 41720282 ↗ Feb 2026 |
| Known as | IVIG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06305793 ↗ |
| Modality | Protein / enzyme biologic | “pharmacotherapy with intravenous immunoglobulin (IVIG)” PMID 41720282 ↗ Feb 2026 |
| Route | Intravenous | “pharmacotherapy with intravenous immunoglobulin (IVIG)” PMID 41720282 ↗ Feb 2026 |